Role of abciximab in the treatment of coronary artery disease.

Unidade de Cardiologia de Intervenção Joaquim Oliveira, Serviço de Cardiologia, Hospital de Santa Maria, Avenida Egas Moniz, 1649-035 Lisboa, Portugal.
Expert opinion on biological therapy (Impact Factor: 3.65). 10/2006; 6(9):935-42. DOI: 10.1517/14712598.6.9.935
Source: PubMed

ABSTRACT Glycoprotein IIb/IIIa complex is a crucial membrane receptor for platelet aggregation, binding platelets to fibrinogen and establishing interplatelet bridges. This receptor is the common end point of the multiple activation pathways of a platelet. Antiplatelet agents, such as aspirin or thienopyridines, including ticlopidine and clopidogrel, inhibit one or more but not all, of these pathways. Inhibitors of the receptor are powerful platelet antiaggregants and include two groups of agents: non-competitive receptor blockers, such as abciximab, and competitive antagonists, such as tirofiban and eptifibatide. Abciximab is a monoclonal antibody that binds to the glycoprotein IIb/IIIa complex, thus blocking the interaction with fibrinogen. It is used for treatment of coronary artery disease, being well-studied in the setting of acute coronary syndromes and percutaneous coronary intervention, in which a rapid and effective antiaggregation is clinically important.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Highly selective molecular binding and the subsequent dynamic protein assemblies control the adhesion of mammalian cells. Molecules that inhibit cell adhesion have the therapeutic potential for a wide range of diseases. Here, we report an efficient synthesis (2-4 steps) of a class of squaramide molecules that mimics the natural tripeptide ligand Arg-Gly-Asp (RGD) that mediates mammalian cell adhesion through binding with membrane protein integrin. In solution, this class of squaramides exhibits a higher potency at inhibiting mammalian cell adhesion than RGD tripeptides. When immobilized on a bio-inert background formed by self-assembled monolayers of alkanethiols on gold films, squaramide ligands mediate vastly different intracellular structures than RGD ligands. Immunostaining revealed that the focal adhesions are smaller, but with a larger quantity, for cells adhered on squaramides than that on RGD ligands. Furthermore, the actin filaments are also more fibrous and well distributed for cell adhesion mediated by squaramide than that by RGD ligands. Quantification reveal that squaramide ligands mediate about 1.5 times more total focal adhesion (measured by the summation of the area of all focal adhesions) than that by natural RGD ligands. This result suggests that cell adhesion inhibitors, while blocking the attachment of cells to surfaces, may induce more focal adhesion proteins. Finally, this work demonstrates that immobilizing new ligands on bioinert surfaces provide a powerful tool to study mammalian cell adhesion.
    Bioorganic & medicinal chemistry 02/2013; 21(8). DOI:10.1016/j.bmc.2013.02.032 · 2.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis is a complex disease process in which genetic, lipid, cellular and immunological factors combine to determine the location, severity and timing of lesion development and clinical events. It has been demonstrated, however, that inflammation governs atherosclerosis during the course of development of atherosclerosis. It has also been demonstrated that regulation of the inflammatory reaction (e.g. statins) is effective in decreasing the cardiovascular events and improving the prognosis of atherosclerotic diseases. Other anti-atherosclerosis agents introduced in this study are adiponectin, testosterone, defibrase, angiotensin-converting enzyme inhibitors, dextromethorphan, paeonol, 15-lipoxygenase inhibitors, curcumin, interferon-beta, quercetin, AGI-1067, peroxisome proliferator-activated receptor gamma ligands and garlic. Some antiplatelet drugs described here are aspirin, clopidogrel and glycoprotein IIb/IIIa receptor antagonist. The mechanism of action of these agents is depicted. A new way of targeting anti-atherosclerosis and antiplatelet drugs to atherosclerosis areas is introduced. The author uses an antioxidized low-density lipoprotein antibody that is also conjugated to a mixture of anti-atherosclerosis agents or antiplatelet drugs to target these agents specifically to the atherosclerosis area. With this kind of targeting, we can use a much higher dose of anti-atherosclerosis agents or antiplatelet drugs and have much fewer side effects.
    Journal of Cardiovascular Medicine 10/2009; 11(1):1-6. DOI:10.2459/JCM.0b013e32832e0af3 · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With many advantages over other therapeutic agents such as monoclonal antibodies, aptamers have recently emerged as a novel and powerful class of ligands with excellent potential for diagnostic and therapeutic applications. Typically generated through Systematic Evolution of Ligands by EXponential enrichment (SELEX), aptamers have been selected against a wide range of targets such as proteins, phospholipids, sugars, nucleic acids, as well as whole cells. DNA/RNA aptamers are single-stranded DNA/RNA oligonucleotides (with a molecular weight of 5-40 kDa) that can fold into well-defined 3D structures and bind to their target molecules with high affinity and specificity. A number of strategies have been adopted to synthesize aptamers with enhanced in vitro/in vivo stability, aiming at potential therapeutic/diagnostic applications in the clinic. In cardiovascular diseases, aptamers can be developed into therapeutic agents as anti-thrombotics, anti-coagulants, among others. This review focuses on aptamers that were selected against various molecular targets involved in cardiovascular diseases: von Willebrand factor (vWF), thrombin, factor IX, phospholamban, P-selectin, platelet-derived growth factor, integrin α(v)β(3), CXCL10, vasopressin, among others. With continued effort in the development of aptamer-based therapeutics, aptamers will find their niches in cardiovascular diseases and significantly impact clinical patient management.
    Current Medicinal Chemistry 08/2011; 18(27):4169-74. DOI:10.2174/092986711797189673 · 3.72 Impact Factor